3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Gastrointestinal
1
CNS
1
Conditions
Neoplasms
4
Lung Neoplasms
3
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Hematologic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Stomach Neoplasms
1
Sarcoma
1
Neuroblastoma
1
Lymphoproliferative Disorders
1
Glioma
1
Adenocarcinoma of Lung
1
Interventions
Oxaliplatin
42
Fluorouracil
27
Capecitabine
24
pembrolizumab
21
S 1 (combination)
19
Paclitaxel
19
Leucovorin
16
Nivolumab
13
Docetaxel
13
sintilimab
12
Drug Therapy
12
Trastuzumab
11
tislelizumab
10
Cisplatin
10
Irinotecan
9
Bevacizumab
8
trastuzumab deruxtecan
7
spartalizumab
7
XELOX
7
Surgical Procedures, Operative
7
Radiotherapy
7
Hyperthermic Intraperitoneal Chemotherapy
7
Biopsy
7
fludarabine
6
disitamab vedotin
6
Cyclophosphamide
6
lenvatinib
5
apatinib
5
Specimen Handling
5
Ramucirumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Stomach Neoplasms
×
capmatinib
×
Clear all
NCT06988475
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled